PERFUSION MEDICAL

Perfusion Medical is commercializing a game-changing drug for the treatment of hemorrhagic shock and other ischemic conditions. The drug has been developed with more than $18 million in DoD funding and more than a dozen published studies from leading research institutions show the potential for the drug to help millions of patients... We are leveraging our 19-million-dollar investment from the US military to commercialize a drug, PM-208, that treats capillary compression due to ischemia - a major unsolved problem in hemorrhagic shock as well as other ischemic injury including acute kidney injury, cardiac bypass disfunction and ischemic reperfusion injury. This is a patent protected drug with a simple formulation, simple mechanism of action strong pre-clinical safety profile. A drug that could help more than 4 million patients annually in the US with a market potential exceeding $10 billion dollars.

Primary location: Reston United States